<?xml version="1.0" encoding="UTF-8"?>
<ref id="B14-pharmacy-08-00108">
 <label>14.</label>
 <element-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Gallant</surname>
    <given-names>J.</given-names>
   </name>
   <name>
    <surname>Lazzarin</surname>
    <given-names>A.</given-names>
   </name>
   <name>
    <surname>Mills</surname>
    <given-names>A.</given-names>
   </name>
   <name>
    <surname>Orkin</surname>
    <given-names>C.</given-names>
   </name>
   <name>
    <surname>Podzamczer</surname>
    <given-names>D.</given-names>
   </name>
   <name>
    <surname>Tebas</surname>
    <given-names>P.</given-names>
   </name>
   <name>
    <surname>Girard</surname>
    <given-names>P.-M.</given-names>
   </name>
   <name>
    <surname>Brar</surname>
    <given-names>I.</given-names>
   </name>
   <name>
    <surname>Daar</surname>
    <given-names>E.S.</given-names>
   </name>
   <name>
    <surname>Wohl</surname>
    <given-names>D.</given-names>
   </name>
   <etal/>
  </person-group>
  <article-title>Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US-380-1489): A double-blind, multicentre, phase 3, randomised controlled non-inferiority trial</article-title>
  <source>Lancet</source>
  <year>2017</year>
  <volume>390</volume>
  <fpage>2063</fpage>
  <lpage>2072</lpage>
  <pub-id pub-id-type="doi">10.1016/S0140-6736(17)32299-7</pub-id>
  <pub-id pub-id-type="pmid">28867497</pub-id>
 </element-citation>
</ref>
